在越南的Mycobacterium结核病中产生多药耐药性和补偿突变
Quang Huy Nguyen1, Thi Van Anh Nguyen2, Anne-Laure Bañuls1,3
1LMI DRISA, Department of Life Sciences, University of Science and Technology of Hanoi (USTH), Vietnam Academy of Science and Technology (VAST), Hanoi, Vietnam.
Tropical medicine & international health : TM & IH
|March 13, 2025
概括
越南的多药耐药结核菌株经常携带突变,以最小的健康成本产生耐药性. 北京基因型菌株显示,与利芬素耐药性相关的补偿突变的患病率更高.
科学领域:
- 微生物学 微生物学
- 遗传学 是一个遗传学.
- 流行病学 流行病学
背景情况:
- 越南是多耐药性结核病菌菌 (MDR-TB) 出现和传播的公认热点.
- 了解耐药性和MDR-TB补偿进化的遗传基础对于有效的治疗和控制至关重要.
研究的目的:
- 来自越南的MDR-TB菌株的补偿进化研究.
- 分析耐药突变,补偿突变和Mycobacterium结核病基因型之间的关联.
主要方法:
- 一项对173种MDR-TB菌株 (耐利芬素和/或异化) 的回顾性研究.
- 关键基因和促进子区域 (rpoA,rpoB,rpoC,katG,inhA,ahpC,gyrA,gyrB,rrs) 的测序.
- 对抗药物突变模式,补偿突变和基因型关联 (北京,欧美,东非-印度) 的分析.
主要成果:
- 观察到高频率的突变赋予了对利芬素 (99.2%) 和异化 (97.0%) 的耐药性.
- 特定突变 (例如,rpoB_Ser450Leu,katG_Ser315Thr) 与高水平的耐药性和低的健身成本有关.
- 与东非 - 印度菌株相比,北京基因型菌株的补偿突变频率与里法辛耐药性相关显著更高 (21.1%与3.3%).
- 在MDR-TB菌株的19.5%中发现了rpoA,rpoB或rpoC的补偿突变,特别是与携带rpoB_Ser450Leu的北京菌株相关.
结论:
- 高级药物耐药性突变 (rpoB_Ser450Leu,katG_Ser315Thr) 与补偿性突变相结合,与越南的MDR-TB北京菌株有很强的联系.
- 基因型背景显著影响了MDR-TB中补偿突变的获得和流行.
相关概念视频
01:28Pulmonary Tuberculosis V
159
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
159
01:36Mismatch Repair
39.8K
Overview
39.8K
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
01:29Pulmonary Tuberculosis I
214
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
214
00:36Viral Mutations
32.1K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
32.1K